308 related articles for article (PubMed ID: 12108972)
21. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins.
Pacchia AL; Adelson ME; Kaul M; Ron Y; Dougherty JP
Virology; 2001 Mar; 282(1):77-86. PubMed ID: 11259192
[TBL] [Abstract][Full Text] [Related]
22. Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication.
Klimatcheva E; Planelles V; Day SL; Fulreader F; Renda MJ; Rosenblatt J
Mol Ther; 2001 Jun; 3(6):928-39. PubMed ID: 11407907
[TBL] [Abstract][Full Text] [Related]
23. Potent inhibition of simian immunodeficiency virus (SIV) replication by an SIV-based lentiviral vector expressing antisense Env.
Braun SE; Lu XV; Wong FE; Connole M; Qiu G; Chen Z; Slepushkina T; Slepushkin V; Humeau LM; Dropulic B; Johnson RP
Hum Gene Ther; 2007 Jul; 18(7):653-64. PubMed ID: 17600461
[TBL] [Abstract][Full Text] [Related]
24. Transduction of cell lines and primary cells by FIV-packaged HIV vectors.
Morris KV; Gilbert J; Wong-Staal F; Gasmi M; Looney DJ
Mol Ther; 2004 Jul; 10(1):181-90. PubMed ID: 15272479
[TBL] [Abstract][Full Text] [Related]
25. Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy.
Anderson JS; Javien J; Nolta JA; Bauer G
Mol Ther; 2009 Dec; 17(12):2103-14. PubMed ID: 19690520
[TBL] [Abstract][Full Text] [Related]
26. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1.
Kim VN; Mitrophanous K; Kingsman SM; Kingsman AJ
J Virol; 1998 Jan; 72(1):811-6. PubMed ID: 9420292
[TBL] [Abstract][Full Text] [Related]
27. High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector.
Fraisier C; Irvine A; Wrighton C; Craig R; Dzierzak E
Gene Ther; 1998 Dec; 5(12):1665-76. PubMed ID: 10023446
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev.
Ragheb JA; Couture L; Mullen C; Ridgway A; Morgan RA
Hum Gene Ther; 1999 Jan; 10(1):103-12. PubMed ID: 10022535
[TBL] [Abstract][Full Text] [Related]
29. Multigene lentiviral vectors based on differential splicing and translational control.
Zhu Y; Feuer G; Day SL; Wrzesinski S; Planelles V
Mol Ther; 2001 Oct; 4(4):375-82. PubMed ID: 11592842
[TBL] [Abstract][Full Text] [Related]
30. [Inhibition of HIV-1 in vitro by combination of vpr and tat specific short hairpin RNA via lentiviral vectors].
Hao YZ; Teng ZP; Yang YS; Sun XN; Ma J; Jin XH; Zeng Y
Bing Du Xue Bao; 2013 Mar; 29(2):126-31. PubMed ID: 23757841
[TBL] [Abstract][Full Text] [Related]
31. Towards developing HIV-2 lentivirus-based retroviral vectors for gene therapy: dual gene expression in the context of HIV-2 LTR and Tat.
Sadaie MR; Zamani M; Whang S; Sistron N; Arya SK
J Med Virol; 1998 Feb; 54(2):118-28. PubMed ID: 9496370
[TBL] [Abstract][Full Text] [Related]
32. Identification of unique reciprocal and non reciprocal cross packaging relationships between HIV-1, HIV-2 and SIV reveals an efficient SIV/HIV-2 lentiviral vector system with highly favourable features for in vivo testing and clinical usage.
Strappe PM; Hampton DW; Brown D; Cachon-Gonzalez B; Caldwell M; Fawcett JW; Lever AM
Retrovirology; 2005 Sep; 2():55. PubMed ID: 16168051
[TBL] [Abstract][Full Text] [Related]
33. A lentiviral vector that activates latent human immunodeficiency virus-1 proviruses by the overexpression of tat and that kills the infected cells.
Macías D; Oya R; Saniger L; Martín F; Luque F
Hum Gene Ther; 2009 Nov; 20(11):1259-68. PubMed ID: 19604078
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of HIV-1 by a Lentiviral Vector with a Novel Tat-Inducible Expression System and a Specific Tropism to the Target Cells.
Farazmandfar T; Haghshenas MR; Shahbazi M
Hum Gene Ther; 2015 Oct; 26(10):680-7. PubMed ID: 26077977
[TBL] [Abstract][Full Text] [Related]
35. Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA.
Mautino MR; Morgan RA
Hum Gene Ther; 2002 Jun; 13(9):1027-37. PubMed ID: 12067436
[TBL] [Abstract][Full Text] [Related]
36. Selective induction of toxicity to human cells expressing human immunodeficiency virus type 1 Tat by a conditionally cytotoxic adenovirus vector.
Venkatesh LK; Arens MQ; Subramanian T; Chinnadurai G
Proc Natl Acad Sci U S A; 1990 Nov; 87(22):8746-50. PubMed ID: 2247444
[TBL] [Abstract][Full Text] [Related]
37. Combination gene therapy: synergistic inhibition of human immunodeficiency virus Tat and Rev functions by a single RNA molecule.
Lisziewicz J; Zeng G; Gratas C; Weinstein JN; Lori F
Hum Gene Ther; 2000 Apr; 11(6):807-15. PubMed ID: 10779158
[TBL] [Abstract][Full Text] [Related]
38. A third-generation lentivirus vector with a conditional packaging system.
Dull T; Zufferey R; Kelly M; Mandel RJ; Nguyen M; Trono D; Naldini L
J Virol; 1998 Nov; 72(11):8463-71. PubMed ID: 9765382
[TBL] [Abstract][Full Text] [Related]
39. Heterologous human immunodeficiency virus type 1 lentiviral vectors packaging a simian immunodeficiency virus-derived genome display a specific postentry transduction defect in dendritic cells.
Goujon C; Jarrosson-Wuilleme L; Bernaud J; Rigal D; Darlix JL; Cimarelli A
J Virol; 2003 Sep; 77(17):9295-304. PubMed ID: 12915545
[TBL] [Abstract][Full Text] [Related]
40. Analysis of trans-dominant mutants of the HIV type 1 Rev protein for their ability to inhibit Rev function, HIV type 1 replication, and their use as anti-HIV gene therapeutics.
Ragheb JA; Bressler P; Daucher M; Chiang L; Chuah MK; VandenDriessche T; Morgan RA
AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1343-53. PubMed ID: 8573391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
